Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates

Karyopharm Therapeutics Inc. (KPTI) shares fell about 68% after the company reported topline results from its Phase 3 XPORT-EC-042 trial. The trial did not meet its primary endpoint of progression-free survival. The stock dropped 68.17% to $2.2350 on Nasdaq from $7.01 prior close.

Karyopharm Therapeutics (KPTI) reported topline results from its Phase 3 XPORT-EC-042 trial of selinexor as maintenance therapy in TP53 wild-type advanced or recurrent endometrial cancer. The trial missed the primary endpoint for progression-free survival, though median PFS was 12.75 months vs 7.43 months with placebo in 236 patients. No new safety signals were reported; full data planned for a medical meeting.

Karyopharm Therapeutics shares fell about 67% to $2.29 after its Phase 3 XPORT-EC-042 endometrial cancer trial missed its primary goal, with no statistically significant progression-free survival improvement versus placebo. Analysts downgraded and cut price targets (e.g., Baird $15 to $3, H.C. Wainwright $13 to $3). Karyopharm said it will scale back endometrial plans and focus on myelofibrosis and multiple myeloma.

– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review – – Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Compelling SVR35 Data and Preliminary Overall Survival Data Observed at the Time of the Topline Results – – Company Plans to Use Long-Term Overall Survival Data from the Ongoing Phase 3 SENTRY Trial to Verify Clinical Benefit – – If Approved, Selinexor in Combination with Ruxolitinib has the Potential to Become the...

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.